Discussion on the Use of Bone Modifying Agents in Metastatic Prostate Cancer - Tian Zhang and Evan Yu Discussion on Patient Selection for Radioligand Therapy in Prostate Cancer - Oliver Sartor and ...

Alicia Morgans: I am going to be talking about incorporating PSMA PETs into registration trials with an example of a study that is relying on a PSMA PET endpoint as the primary endpoint in the study.

David Matheson discusses the patient perspective on radiographic progression-free survival as a clinical trial endpoint. Dr. Matheson argues that imaging-based progression is more ...

Tyler Seibert outlines his approach to radiation therapy for the primary tumor in metastatic hormone-sensitive prostate cancer. He summarizes three randomized trials that consiste ...

Silke Gillessen speaks with Neeraj Agarwal about the Advanced Prostate Cancer Consensus Conference, marking its 10th anniversary edition in Lugano. Dr. Gillessen describes APCCC's focus on daily ...

Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...

Sophia Coraci discusses an analysis of 104 treatment-naive prostate cancer patients correlating PSMA PET SUVmax with Decipher genomic classifier scores. PSMA PET imaging occurred within 35 days of ...

Muscle-invasive bladder cancer (MIBC) has historically been managed with neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy (RC), a strategy associated with substantial morbidity ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Phillip Koo: Welcome to UroToday. Two years ago, UCSF, UCLA and PCF started a wonderful meeting called PSMA & Beyond. This year in March, we are going to again host another meeting under the ...

Paul Nguyen discusses the Artera AI prostate test for post-prostatectomy BCR. The test combines clinical factors with AI-analyzed digital pathology from prostatectomy specimens. Validation using RTOG ...

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions for patients with prostate cancer across the disease spectrum. The Guidelines sections included in this article ...